Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266851 · ClinicalTrials.gov registry record · Phase 3
AZMATICS: AZithroMycin/Asthma Trial In Community Settings
A Phase 3 study of Asthma, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 3
- Development phase
- 97
- Enrollment target
- 5
- Study locations
NCT00266851 is a Phase 3 study of Asthma that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 97 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00266851, a Phase 3 study of Asthma, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 97 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assess the effectiveness of the azalide macrolide azithromycin in adults with persistent asthma. Research Question: Will a 12-week treatment with the antibiotic, azithromycin, result in a statistically significant and clinically meaningful improvement in overall asthma symptoms and other patient-oriented asthma outcomes one year after initiation of treatment of adult primary care patients with asthma? Experimental Design: The investigators propose a one-year randomized, placebo-controlled, blinded (investigator, patient, data collector, data analyst) trial of 12 weekly doses of azithromycin/placebo as adjunctive therapy (in addition to usual care) along with a parallel observational cohort who will participate 'open label' in 100 adult asthma patients recruited from practice-based research networks (e.g., Wisconsin Research and Education Network (WREN) and others). This "practical clinical trial" will (1) enroll a representative sample of asthma patients encountered in the practices of primary care physicians, (2) employ standard clinical trial methodology to ensure internally valid results and (3) measure outcomes important to patients, so that the results will be valid and applicable to the kinds of asthma patients encountered by family physicians and other primary care providers. Active study sites - * Wisconsin: Augusta, Cross Plains, La Crosse, Marshfield, Milwaukee, Madison, * Mauston, Rice Lake, Tomah, Wausau * Colorado: Monument * Illinois: Peoria * Nevada: Reno * North Carolina: Granite Falls * North Dakota: Minot * Ohio: Cleveland, Berea * Oklahoma: Ardmore, Claremore, Edmond, Lawton, Oklahoma City, Stroud, Tulsa, Weatherford * Rhode Island: East Providence
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Azithromycin
Study Locations (5)
Illinois
- ANSR - Peoria
Kansas
- AAFP National Research Network - Kansas City
Ohio
- RAP - Cleveland Clinic - Cleveland
Oklahoma
- University of Oklahoma Health Sciences Center (OUHSC) and Oklahoma Physicians Resource/Research Network (OKPRN) - Oklahoma City
Wisconsin
- Wisconsin Research and Education Network (WREN) - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00266851
The ClinicalTrials.gov registry entry for NCT00266851 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (94% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00266851 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Kansas, Ohio.
Frequently Asked Questions
What is clinical trial NCT00266851 about?
NCT00266851 is a clinical study titled "AZMATICS: AZithroMycin/Asthma Trial In Community Settings". The purpose of this study is to assess the effectiveness of the azalide macrolide azithromycin in adults with persistent asthma. Research Question: Will a 12-week treatment with the antibiotic, azithromycin, result in a statistically significant and clinically meaningful improvement in overall asth...
What is the current status of trial NCT00266851?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 97 participants. The study started on 2006-01. Estimated completion is 2010-11.
What conditions does trial NCT00266851 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00266851?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).
Who is sponsoring clinical trial NCT00266851?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00266851 being conducted?
This trial has 5 study locations across Illinois, Kansas, Ohio, Oklahoma, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.